Alnylam Pharmaceuticals is a leading RNAi therapeutics company based in Boston, MA. They have pioneered the translation of RNA interference (RNAi) into a new class of medicines, with the potential to improve the lives of people worldwide. Through their innovative science, commitment to patients, and a deep pipeline of investigational RNAi therapeutics, Alnylam has established itself as a leader in the field, aiming to help people live longer, healthier, and fuller lives.
Their RNAi therapeutics are based on the breakthrough discovery of how genes are naturally regulated within cells. By using RNAi to silence or turn off specific disease-causing genes, Alnylam's medicines have the potential to treat a wide range of diseases. With a robust pipeline of investigational RNAi therapeutics, Alnylam is continuously working towards addressing complex health and societal challenges, aiming to make a broad impact beyond just rare diseases.
Generated from the website